Report as on 28 July 2022 at 12:07 AM

POOR GROWTH IN
LONG TERM NET SALES
Negative Syngene Intl.
Results in Jun 22

Strong sell
Mildly Bearish
Technical Trend
CMP: 575.25
Very Expensive STOCK INFO:
Valuation BSE – 539268/ NSE – SYNGENE
Market Cap - Large Cap (Rs. 22,886 cr)
Sector – Pharma
Market 52 w H/L (Rs.) – 686.3/510.1
Dividend Yield: 0.17%

Underperformance Debt Equity: -0.08%

Return on Equity: 12.76%
Last 1 Year Price to Book: 6.96

www.marketsmojo.com
Syngene Intl.
CMP: 575.25 27 Strong Sell
Report as on 28 July 2022 at 12:07 AM
Strong Sell Sell Hold Buy Strong Buy

This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and a
violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

WHY IT’S A STRONG SELL? IS THIS STOCK FOR YOU?

Medium Risk, Low Return (1 Year)
Poor long term growth as Net Sales has grown by
an annual rate of 12.98% and Operating profit at Absolute Risk Volatility
8.91% over the last 5 years Adjusted
The company has declared negative results in Syngene Intl. -6.23% -0.20 31.10%
Jun'2022 after 1 consecutive positive quarters SENSEX 6.16% 0.36 17.27%
-PAT(Q) At Rs 73.90 cr has Fallen at -29.7 %
-OPERATING CF(Y) Lowest at Rs 582.20 Cr How much should you sell? - All quantity irrespective of
whether you are making profits or losses
-PBT LESS OI(Q) Lowest at Rs 77.30 cr.
When to re-enter? - We will constantly monitor the
Stock is technically in a Mildly Bearish range company and review our call based on new data
-The technical trend has deteriorated from Sideways
on 20-Jul-22 and has generated -4.86% returns since RETURNS SUMMARY (Price + Dividend)
then The stock gave a total returns of -6.15% in the last 1 year
-A key technical factor - KST has been Bearish since Underperforming Sensex returns of 6.16%
20 Jul 2022 200%

With ROE of 12.8, it has a Very Expensive

100%
valuation with a 7 Price to Book Value
-The stock is trading at a discount compared to its 0%
average historical valuations
-Over the past year, while the stock has generated a -100%
return of -6.23%, its profits have risen by 5.7% ; the
Ja 1 9

O 21
Fe 2 0

Fe 2 1
Se -1 9

Se 0

2
Au 21

Ju 2
D -2 0

Ap 21
Ju 2 1

D -2 1

Ap 22
Ju 2 2
M 20
M -2 0

Ju 0
N 19

O 20
l- 2

l- 2
2
-2
-

g-
-

-
n-

n-
b-

b-
r-

r-
n-
p-

p-

PEG ratio of the company is 10.5

ov
l

ec

ec
ct

ct
ar
ay
Ju

Underperformed the market in the last 1 year Syngene International Ltd SENSEX
-Even though the market (BSE 500) has generated
returns of 4.88% in the last 1 year, the stock has
Investors Returns (3 years) –
hugely underperformed and has generate negative
returns of -6.23% returns Period 6M 1Y 2Y 3Y
Stock (%) 3.78% -6.15% 26.28% 84.71%
Sector (%) -3.70% -3.70% 25.90% 65.21%
WHAT ARE OTHER FACTORS? Sensex (%) -2.55% 6.16% 47.14% 47.34%
Company has a low Debt to Equity ratio (avg) at 0
times

DO YOU HAVE OTHER BETTER CHOICES?

Within same sector Within same market cap
There are no stocks in Pharma industry which we would Coal India Ltd.
recommend at this point
Get Verdict Report

MOJO PROFESSIONAL 1
Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

BEFORE PROCEEDING AHEAD

This Real-Time Stock Analysis service is only for
PAID SUBSCRIBERS of www.marketsmojo.com

This Real-Time Stock Analysis Report was

generated on 28th July, 2022 at 12:07 AM, and
may not be valid if you are reading it later.

Some factors/data, as well as the buy/sell/hold call

might have changed.

To access the LATEST version of this report.

Click Here

MOJO PROFESSIONAL 2
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

GROWTH

POOR LONG TERM GROWTH AS NET SALES

HAS GROWN BY AN ANNUAL RATE OF
12.98% AND OPERATING PROFIT AT 8.91%
OVER THE LAST 5 YEARS

Poor Growth in Net Sales 3000Cr

2,654
of 13.0% CAGR
13.0% Company has experienced an increase
2,011
2,357

CAGR in its Net Sales in each of the past 5

2000Cr 1,840
1,538
consecutive years 1,200
Company’s Net Sales growth has 1000Cr
increased in each of the past 5
consecutive years
Net Sales has seen a high growth of 0Cr
12.6% over previous period Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022

Poor Growth in Operating 600Cr

Profit of 8.9% CAGR

8.9%
482
429
Company has experienced an increase
CAGR in its Operating Profit in each of the
400Cr 372 381

past 5 consecutive years 270 272

Company’s Operating Profit growth 200Cr

has increased in each of the past 5
consecutive years
Operating Profit has seen a high 0Cr
growth of 12.35% over previous Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022

period

Net Profit of 7.3% CAGR 600Cr

7.3% Company has experienced an increase

in its Net Profit in each of the past 5 394
417

CAGR consecutive years

400Cr
336 343
309
287
Company’s Net Profit growth has
increased in each of the past 5 200Cr
consecutive years

0Cr
Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022

MOJO PROFESSIONAL 3
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

FINANCIAL TREND

THE COMPANY HAS DECLARED NEGATIVE

RESULTS IN JUN'2022 AFTER 1
CONSECUTIVE POSITIVE QUARTERS

Near term PBT trend is negative 164.4

Rs 77.3 cr PBT less Other Income (Rs Cr)

Lowest at Rs 77.30 cr. 115.5
100
PBT - Quarterly in the last five quarters 82.4 77.3

Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022

Near term PAT trend is very

negative
-29.7% 147.8

PAT (Rs Cr) 104

PAT Growth At Rs 73.90 cr has Fallen at -29.7 %
91.61
77.3 73.9
over average PAT of the previous four quarters of Rs
105.18 Cr

Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022

The company's cash revenues 677.4 698

Rs 582.2 from business operations are 582.2

falling
cr Operating Cash Flows (Rs Cr)
Operating Cash Lowest at Rs 582.20 Cr
Flow- Annually in the last three years

Mar 2020 Mar 2021 Mar 2022

MOJO PROFESSIONAL 4
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

FINANCIAL TREND

Increased income from non

Rs 15.5 cr business activities may not be 15.5
14.7

sustainable 12.3 12.9 12.9

Non Operating
Non Operating Income
Income -
Highest at Rs 15.50 cr
Quarterly
in the last five quarters

Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022

Jun'22 Mar'22 Change%

Net Sales 644.5 758.1 -15.0%
Key Operating Profit (PBDIT) excl Other Income 172.8 250.3 -31.0%
Result Interest 9.4 5.6 67.9%
Highlights Exceptional Items 0.0 0.0
Consolidated Net Profit 73.9 147.8 -50.0%
Operating Profit Margin (Excl OI) 26.8 33.0 -6.2%
Consolidate- figures in Rs
Cr

MOJO PROFESSIONAL 5
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

TECHNICALS

STOCK IS TECHNICALLY IN A MILDLY

BEARISH RANGE
Mildly Bearish Daily Moving Averages indicating near term price weakness
Current Price 50 Day Moving Average 200 Day Moving Average

575.25 559.84 581.28

Factors with downward momentum

Indicator Technical Trend
MACD Mildly Bearish (monthly)
Bollinger Band Mildly Bearish (weekly)
Bollinger Band Mildly Bearish (monthly)
KST Bearish (weekly)
KST Mildly Bearish (monthly)
Dow Theory Mildly Bearish (monthly)

Underperformed the market in the last 1 year

3 Months 1 Year 3 Years
84.55%
4.88%
56.10%
-3.36%

-6.83%
-6.23%

Stock BSE 500 Stock BSE 500 Stock BSE 500

MOJO PROFESSIONAL 6
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

VALUATION

WITH ROE OF 12.8, IT HAS A VERY

EXPENSIVE VALUATION WITH A 7 PRICE TO
BOOK VALUE
Expensive

Very Expensive Lupin

Syngene Intl.

valuation
Glaxosmi.
Laurus
Ipca Labs.
Pharma
Labs

Valuation

as compared to its Fundamentals

Attractive
Weak Fundamental Strong

Price to Book Value vs ROE

Attractive 24 12
Fundamental

Valuation
as compared to its 12 7.2

past valuations 0 2.4

7

2
18

19

20

21
01

01

01

02

02

02
20

20

20

20
-2

-2

-2

-2

-2

l- 2
n-

n-

n-

n-
ec

ec

ec

ec

ec

Ju
Ju

Ju

Ju

Ju
D

Company Valuation Price to Book PE Ratio PEG Ratio Dividend

Ratio Yield
Key
Valuation Syngene Intl. Very Expensive 7 55.3 10.5 0.2%

Multiples Lupin Risky 2.4 -19 0 1.6%

vs Peers Laurus Labs Expensive 8.2 33.3 0 0.4%
Ipca Labs. Expensive 4.6 28.3 0 0.4%
Glaxosmi. Pharma Expensive 9.2 14.7 0.1 6.2%

MOJO PROFESSIONAL 7
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

RETURNS

UNDERPERFORMED THE MARKET IN THE

LAST 1 YEAR
Even though the market 200%
(BSE 500) has generated
returns of 4.88% in the last 100%

1 year, the stock has

-6.23% hugely underperformed 0%

DOWN and has generate -100%

negative returns of -6.23%

Ja 1 9

O 20

Se -2 1

Ja 2 1
Fe 2 0
Se -1 9

Au 0

2
Au 21
Ap 21
D -2 0

Ju 2 1
M 20

M 22
M -2 0

M -2 2
N 19

Ju 0

N 21

Ju 2
returns

l- 2

l- 2
-2

-2
-

g-

-
-

n-
b-
r-
n-

n-
p-

p-
ov

ov
l

ec
ct
ar

ar
ay

ay
Ju
Syngene International Ltd BSE500

Inconsistent Performance against Large Cap

companies
Syngene International Ltd has not been a
consistent performer in the YTD

3rd
Quartile
4th
Quartile
1st
Quartile
Stock has been in the 4th quartile in 2021
and in 3rd in YTD period

YTD 2021 2020

-7.20% -3.08% 99.78%

Company 1 Month 3 Month 1 Year 3 Years

Syngene Intl. 1.23% -6.83% -6.23% 84.55%
Return
Sun Pharma.Inds. 6.98% -1.34% 29.89% 103.2%
Comparison
with Peers Divi's Lab. 3.08% -16.42% -20.97% 127.18%
Closest peers by Cipla 4.47% -0.38% 6.68% 83.06%
market cap
Dr Reddy's Labs -0.8% 5.13% -11.51% 58.45%

MOJO PROFESSIONAL 8
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

FACTORS
WORKING
FOR THE COMPANY


MOJO PROFESSIONAL 9
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

MANAGEMENT RISK

AVERAGE LONG TERM FUNDAMENTAL

STRENGTH WITH AN AVERAGE RETURN ON
EQUITY (ROE) OF 14.85%

ROE
The company has been able to generate a Return on Equity
14.85% ROE
(avg) of 14.85% signifying average profitability per unit of
shareholders funds

Dividend Payout Ratio

An average Dividend Pay-out ratio of 10.13% may signify the
10.13%
Dividend Payout Ratio
company is not able to payback profits to shareholders at this
point

Tax Ratio
High Tax Ratio signifies that the profits generated by the
18.67% Tax Ratio
company are real and it is making adequate contributions
towards by paying due taxes

Institutional Holding
High Institutional Holdings at 18.33%- These investors have
18.33%
Institutional Holding
better capability and resources to analyse fundamentals of
companies than most retail investors

MOJO PROFESSIONAL 10
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

CAPITAL STRUCTURE

COMPANY HAS A LOW DEBT TO EQUITY

RATIO (AVG) AT 0 TIMES
Total Debt Debt to Equity Ratio
Low Debt to Equity Ratio Jun 2022 1,021.60 -0.14
Company’s average Debt to Equity ratio over the past few years Jun 2021 883.50 -0.16
is low at -0.14 times
Jun 2020 777.10 -0.06
No clear trend in Debt to Equity Ratio numbers Jun 2019 657.80 -0.02
Jun 2018 1,119.50 -0.02

Total Debt EBIT to Interest

Healthy EBIT to Interest Jun 2022 1,021.60 14.23
Company has healthy average EBIT to Interest ratio of 14.23 Jun 2021 883.50 12.69
times
Jun 2020 777.10 11.42
EBIT to Interest has seen a high growth of 16.67% over Jun 2019 657.80 17.39
previous period
Jun 2018 1,119.50 18.66

MOJO PROFESSIONAL 11
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

RESULT
ANALYSIS 

MOJO PROFESSIONAL 12
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

QUARTERLY VARIANCE

QUARTER RESULTS VARIANCE ANALYSIS

Jun'22 Mar'22 QoQ Jun'21 YoY Comments
Total Operating income 645 758 -15% 595 8.4%
Total Expenditure (Excl Depreciation) 472 508 -7.1% 430 9.8%
Operating Profit (PBDIT) excl Other Income 173 250 -31% 165 4.7%
Other Income 16 15 5.4% 12 26% High Growth in previous quarter
and same quarter last year
Operating Profit (PBDIT) 188 265 -28.9% 177 6.2%
Interest 9 6 67.9% 8 19% High Growth in previous quarter
and same quarter last year
Exceptional Items 0 0 0% 0 0%
Depreciation 86 80 7.2% 75 15.3% High Growth in previous quarter
and same quarter last year
Profit Before Tax 93 179 -48.2% 95 -2% QoQ and YoY decrease
Tax 19 31 -39.6% 17 8.6%
Provisions and contingencies 0 0 0% 0 0%
Net Profit 74 148 -50% 77 -4.4% QoQ and YoY decrease
Share in Profit of Associates 0 0 0% 0 0%
Minority Interest 0 0 0% 0 0%
Other related items 0 0 0% 0 0%
Consolidated Net Profit 74 148 -50% 77 -4.4% QoQ and YoY decrease

Consolidate results triggered in Rs Cr

Margins
Jun'22 Mar'22 Dec'21 Sep'21 Jun'21 Avg. (4 Comments
Qtrs)
OPM 26.8% 33.0% 31.7% 29.1% 27.8% 30.4% Lower than average (4 Qtrs)
GPM 27.8% 34.2% 32.3% 26.0% 28.5% 30.2% Lower than average (4 Qtrs)
NPM 11.5% 19.5% 16.2% 10.9% 13.0% 14.9% Lower than average (4 Qtrs)

MOJO PROFESSIONAL 13
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

ANNUAL RESULT

NET SALES - YOY GROWTH IN YEAR ENDED

MAR 2022 IS 19.22% VS 8.57% IN MAR 2021
Consolidated Net Profit: YoY Growth in year ended Mar 2022 is -2.25% vs -1.75% in Mar
2021
Operating Profit (PBDIT) excl Other Income: YoY Growth in year ended Mar 2022 is
18.50% vs 8.72% in Mar 2021
Interest: YoY Growth in year ended Mar 2022 is -13.00% vs -19.94% in Mar 2021 19.22%
Operating Profit Margin (Excl OI): YoY Growth in year ended Mar 2022 has fallen from Mar NET SALES
2021

Mar'22 Mar'21 Change(%)

Net Sales 2,604.20 2,184.30 19.22%
Key Operating Profit (PBDIT) excl Other Income 796.10 671.80 18.50%
Annual Interest 24.10 27.70 -13.00%
Results Exceptional Items -30.70 35.00 -187.71%
Consolidated Net Profit 395.80 404.90 -2.25%
Operating Profit Margin (Excl OI) 30.57 30.76 -0.19%
Figures in Rs Cr | Seasonal companies are compared with the same quarter last year

Net Sales-YoY Growth in year ended Mar 2022 is 19.22% vs Consolidated Net Profit-YoY Growth in year ended Mar 2022
8.57% in Mar 2021 is -2.25% vs -1.75% in Mar 2021
4000 500
412.10 404.90 395.80
2,604.20 331.60
305.40
2,011.90 2,184.30
1,825.60
2000 1,423.10 250

0 0
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022

Operating Profit (PBDIT) excl Other Income-YoY Growth in Operating Profit Margin (Excl OI)-YoY Growth in year ended
year ended Mar 2022 is 18.50% vs 8.72% in Mar 2021 Mar 2022 has fallen from Mar 2021
1000 50
796.10
671.80
617.90 29.40 30.71 30.76 30.57
536.80 27.47
500 390.90 25

0 0
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022

Figures in Rs Crore

MOJO PROFESSIONAL 14
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

BALANCESHEET AND CASHFLOW

BALANCE SHEET AND CASH FLOW

ANALYSIS

2.83% Borrowings
Mar'22
1,321.10
Mar'21
1,284.70
Change%
2.83%

Increase
Other Long Term Liabilities 471.40 364.40 29.36%
Fixed Assets 2,481.90 2,288.50 8.45%
Investments 308.80 316.30 -2.37%
in Borrowings in quarter Current Assets 2,205.90 1,806.70 22.10%
ended Mar 2022 vs in
Figures in Rs Cr
Mar 2021

Other Long Term Liabilities: YoY Growth in year ended Mar 2022 is 29.36% vs -10.47% in Mar 2021
Fixed Assets: YoY Growth in year ended Mar 2022 is 8.45% vs 7.37% in Mar 2021
Investments: YoY Growth in year ended Mar 2022 is -2.37% vs 327.43% in Mar 2021
Current Assets: YoY Growth in year ended Mar 2022 is 22.10% vs 12.04% in Mar 2021

Cash From Operation - YoY Growth in year ended Mar

-17.20% 2022 is -17.20% vs 3.56% in Mar 2021
Mar'22 Mar'21 Change%
GROWTH Cash Flow from Operating Activities 580.60 701.20 -17.20%
Figures in Rs Cr

750 701.20
677.10
630.40
580.60

500 446.20

250

0
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022

MOJO PROFESSIONAL 15
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

SHAREHOLDING

MAJORITY SHAREHOLDERS : PROMOTERS

Majority shareholders: Promoters

Mutual Funds
Pledged Promoter Holdings: None 2.79%

Mutual Funds: Held in 17.00 Schemes (2.79%) FIIs

14.12%
FIIs: Held by 176 FIIs (14.12%)
Other
Promoter with highest holding: Biocon Limited (69.99%) 0.83%

Promoters Non Institution

Highest Public shareholder: Uti-unit Linked Insurance Plan 70.29% 10.56%
(1.22%) Other DIIs
1.42%
Individual Investors Holdings: 9.03%

Promoter holding-Promoter holding has decreased by -0.12% FII Holdings-FII holding has increased by 0.45%
100% 20%
70.43% 70.42% 70.41% 70.41% 70.29% 14.40% 14.07% 13.82% 13.67% 14.12%

50% 10%

0.00% 0.00% 0.00% 0.00% 0.00%

0% 0%
Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022

MF Holdings-MF holding has decreased by -0.47% Other DII Holdings-Other DII holding has increased by 0.25%
5% 2%
3.77% 4.03%
3.64% 1.42%
3.26%
2.79% 1.17%
1.00%
2.5% 1% 0.79% 0.80%

0% 0%
Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022

Figures in Rs Crore

MOJO PROFESSIONAL 16
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

PEER COMPARISION

PEER COMPARISON
Syngene Intl. Ipca Labs. Glaxosmi. Pfizer Ajanta Pharma
Pharma
Size
Market Cap (Cr.) 23,062 25,028 24,586 18,965 16,303
Annual Sales (TTM) (Cr.) 2,654 5,830 3,305 2,611 3,341
Annual Net Profit (TTM) (Cr.) 417 883 1,678 613 713
Growth Factors (TTM)
Net Sales Growth 1 year 12.6% 7.6% -1.1% 16.6% 15.6%
Operating Profit Growth 1 year 12.5% -19.4% 8.5% 19.6% -8.9%
Net Profit Growth 1 year 5.7% -22.5% 293.6% 23.1% 9%
Net Sales Growth 5 year 13% 15.6% 1.3% 5.8% 10.8%
Operating Profit Growth 5 year 8.9% 28.3% 7.5% 20.3% 5.6%
Net Profit Growth 5 year 7.3% 25.7% 56% 19.3% 7.1%
Capital Structure Factors
EBIT to Interest 18.9 140 357.2 68.7 78.8
Debt to EBITDA 1.3 0.6 0 0.1 0
Net Debt to Equity -0.1 -0.1 -1.1 -0.6 -0.1

Sales to Capital Employed 0.9 1.2 9 2.3 1.1

Management Quality Factors
ROCE (latest) 16% 21.8% -427.6% 61.8% 27.2%
ROE(latest) 12.8% 16.1% 63.1% 23.7% 21.8%
Tax Ratio 18.7% 19.8% 50.5% 20.7% 21.6%
Operating CF to Net Profit 138% 96.9% 48.3% 85.9% 78.9%
Dividend Payout Ratio 10.1% 11.5% 141.9% 32.2% 12.6%
Valuation Factors
PE Ratio 55.3 28.3 14.7 31 22.9
Price to Book 7 4.6 9.2 7.3 5
PEG Ratio 10.5 - 0 1.3 2
Dividend Yield 0.2% 0.4% 6.2% 0.8% 0.5%
EV to EBITDA 28.4 18.7 27.9 20.9 17.2
EV to Capital Employed 7.5 5 -130.2 15.7 5.4
Shareholding
Promoter Holdings 70.3% 46.3% 75% 63.9% 70.5%
Promoter Pledged Holdings - - - - -
Total Institutional Holding 18.3% 44.3% 12.8% 17.4% 21.2%
FII Holdings 14.1% 10.6% 2.2% 2.6% 8.3%
Returns
1 Month 1.1% 8.2% -2.9% 0.8% 1%
3 Months -7.2% -1.8% -8.5% -2.2% 12.8%
YTD -7.3% -8.8% -17.3% -18.1% -13.5%
1 Year -6.2% -11.6% -12.9% -31.1% -14%
3 Years 84.6% 108.5% 20.4% 30.5% 114.8%

MOJO PROFESSIONAL 17
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

COMPANY BACKGROUND

COMPANY BACKGROUND

About the Company

Syngene International Limited is an internationally reputed custom research and
INDUSTRY : Pharma manufacturing organisation, which supports R&D programs from lead generation
to clinical supplies. The company was promoted by Biocon and Kiran Mazumdar
Shaw, a promoter of Biocon Limited. The company was formed with objectives of
22,886 cr (Large Cap) providing contract research service to overseas customer in the field of synthetic
chemistry, molecular biology and custom synthesis.

Part of NIFTY FREE

MIDCAP 100

Board of Directors
Kiran Mazumdar Shaw Chairperson

John Mccallum Marshall Non Executive Director

Shaw
Non Executive Director
Catherine Patricia
Independent Director
Rosenberg
Independent Director
Paul Frederick
Blackburn

Vijay Kuchroo

5 more board of directors

Company Coordinates

Company Details: Registrat Details:

Biocon Sez, Biocon Park, No 2 & 3, Bommasandra, Industrail Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot
Area, Iv Pahse, Jigani Link Rd Bengaluru Karnataka : 560099 No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial
Tel: 080-28082037 District, Nanakramguda, Serilingampally, Mandal Ranga
Fax: 080 - 28523423 Reddy Dist, Hyderabad
Email: investor@syngeneintl.com
Website: www.syngeneintl.com

MOJO PROFESSIONAL 18
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

MOJO PROFESSIONAL FEATURES

WITH MOJO PROFESSIONAL GET

UNLIMITED ACCESS TO-

1
STOCK SCORE, Buy/Hold/Sell calls on ALL listed companies
With a success rate of over 82% get Buy/Sell/Hold calls on all 4000 listed stocks with detailed
rationale and research reports

2
MODEL PORTFOLIOS, Choice of 3 Outperforming portfolios
Invest in your choice of 3 model portfolios, with an impeccable track record. We will create it and
track it for you. All you have to do is decide the amount you want to invest, choose your risk profile
and start

3
MOJO STOCKS, Top 1% stocks
Invest in your choice of 3 model portfolios, with an impeccable track record. We will create it and
track it for you. All you have to do is decide the amount you want to invest, choose your risk profile
and start

4
PORTFOLIO SERVICES, active advice on your portfolio
Upload your portfolio in seconds from any broker and this unique feature helps you to weed out
underperforming companies and invest in better quality companies. We track & advise you on your
portfolio, 24/7

5
STOCK OF THE MONTH, the best stock to invest each month
Every month – If you want to buy the best 1 stock to buy, which will it be? Every 10th of the month,
you will receive a handpicked stock from our CIO-Sunil Damania.

6
SCREENERS, make your own stock selection model
Want to select companies based on your favorite parameters? Our 2 powerful screeners will help you
to do the same across hundreds of pre chosen parameters you can pick from. Make your own
formula

7
VERDICT, real time research reports on all listed companies
Real Time research service across all companies. The detailed research report changes every minute,
taking into account of all the things that affect a stock. Research your stock and also get alternatives
to betters stock in the same Industry/Market Cap.

8
SWITCHER How to Switch to better stocks
Real Time research service across all companies. The detailed research report changes every minute,
taking into account of all the things that affect a stock. Research your stock and also get alternatives
to betters stock in the same Industry/Market Cap.

Visit www.marketsmojo.com for more information

MOJO PROFESSIONAL 19
This research report has been created by www.marketsmojo.com exclusively for rahimfpathan@gmail.com. You may not copy, reproduce, distribute, publish, display,
perform, modify, create derivative works, transmit, or in any way exploit any such content. Unauthorized usage is an infringement of our intellectual property rights and
a violation of law and it may also result in cancellation of your subscription package without any refund and may lead to legal action.

Syngene Intl. STRONG SELL | Report as on 28 July 2022 at 12:07 AM

DISCLAIMER

DISCLAIMERS
Mojo Markets Private Limited (“the Company”), which owns marketsmojo.com (“the website”) is engaged in the
business of operating the website.

This research report (“Report”) is for the personal information of the authorized recipients and is not for public
distribution and should not be reproduced or redistributed to any other person or in any form without the Company’s
prior permission. The information provided in the Report is from publicly available data, which we believe, are reliable.
While reasonable endeavors have been made to present reliable data in the Report so far as it relates to both current
as well as historical information, the Company does not guarantee the accuracy or completeness of the data in the
Report. Accordingly, neither the Company nor its shareholders, directors, officers, employees, advertisers, content
providers and licensors are responsible either jointly or severally for any loss or damage that may arise to any person
from any inadvertent error in the information contained, views and opinions expressed in the research reports.

Investment in securities is subject to market risks. Past performance should not be construed as a guarantee for future
returns and no representation or warranty, express or implied, is made regarding future performance. Investments in
equity and equity related securities involve a high degree of risks and the users should be clearly aware that prices of
securities as well as the income derived from these securities can fall as well as rise.

The Report also includes the analysis and views of our research team. The Report is purely for information purposes
and should not be construed as an investment recommendation or advice or an offer or solicitation of an offer to buy
or sell any securities.

The opinions expressed in the Report are those as on the date of the Report and are liable to change from time to time
without notice. The Company or any persons connected with it do not accept any liability arising from the use of this
Report.

Investors should not solely rely on the information contained in this Report and must make investment decisions
based on their own investment objectives, judgment, risk profile and financial position. The recipients of this Report
should take professional advice before acting on this information.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of
or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use
would be contrary to local law, regulation or which would subject the Company and its affiliates to any registration or
licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all
jurisdictions or to all category of investors.

The Company is also a SEBI registered Investment Advisor (“IA”). The Company and its associates do not own any
securities of the subject company/ies mentioned in the report as on the date of this research report.

The Research team engaged in the preparation of this Report and/or their relatives collectively did not own more than
1% of the equity in the subject company/ies mentioned in this Report (unless otherwise mentioned in such Report) nor
did they have any other material conflict of interest on the date of this Report.

None of the members of the research team engaged in preparation of this Report (unless otherwise mentioned in such
Report) have served as an officer, director or employee of the subject company in the past twelve months.

No disciplinary action has been taken on the Company by any regulatory authority which can impact the Equity
Research Analysis.

We hereby expressly disclaim any implied warranties imputed by the laws of any jurisdiction other than Mumbai. We
consider ourselves and intend to be subject to the jurisdiction only of the courts of the Mumbai in India and we shall
be governed only by the laws as applicable in India. Even though the site has global access, we are not governed by any
laws of any jurisdiction other than India.

MOJO PROFESSIONAL 20